ASML
ASML Holding N.V.
ASML has a slight edge over COHR overall, supported by stronger valuation and stronger fundamentals.
COHR
Coherent, Inc.
COHR has slightly lower modeled downside risk, despite its lower overall score.
ASML Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Strong |
ASML's profitability, cash flow and balance sheet are currently strong. There isn't enough data to rate its revenue.
COHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Healthy |
COHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
ASML PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $1,375 | -8.2% |
| Current | 39x | $1,497 | — |
| Fair | 43x | $1,684 | +13% |
| Expensive | 56x | $2,177 | +45% |
Historical ranges are pointers, not guarantees.
ASML has the edge over COHR in the historical PE scenario, which offers more potential upside but is not a forecast.
COHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $232 | — |
| Cheap | 27x | $130 | -44% |
| Fair | 34x | $165 | -29% |
| Current | 48x | $232 | — |
| Expensive | 184x | $886 | +282% |
Historical ranges are pointers, not guarantees.
COHR's PE is in its fair range at 48x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
ASML Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ASML, with profitability improving. However, they disagree widely on these estimates.
COHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for COHR, with profitability improving.
ASML Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $38.88 | +44% |
| Q2 2026 | $30.61 | +15% |
| Q3 2025 | $26.91 | +38% |
| Q2 2025 | $26.68 | +40% |
| Q1 2025 | $24.60 | +22% |
| Q4 2024 | $21.42 | -2.9% |
| Q3 2024 | $19.46 | -8.4% |
| Q2 2024 | $19.11 | -7.5% |
COHR has the stronger earnings trend. Trailing diluted EPS is up 58% for ASML versus COHR up 580%.
COHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.69 | +142% |
| Q3 2026 | $4.83 | +580% |
| Q2 2026 | $4.12 | +$4.64 |
| Q1 2026 | $2.11 | +$2.34 |
| Q4 2025 | $1.03 | +$1.44 |
| Q3 2025 | $0.71 | +$1.94 |
| Q2 2025 | -$0.52 | +$1.32 |
| Q1 2025 | -$0.23 | +$2.64 |
| Q4 2024 | -$0.41 | +$2.41 |
COHR's earnings per share have climbed steadily: $4.83 over the past year, about seven times what it earned the year before, and higher year over year for 10 quarters in a row.
ASML Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +55% |
| Q2 2026 | $10.4B | +21% |
| Q1 2026 | $9.7B | +13% |
| Q4 2025 | $10.8B | +4.9% |
| Q3 2025 | $8.3B | +0.7% |
| Q3 2025 | $8.3B | +0.7% |
| Q2 2025 | $8.5B | +23% |
| Q1 2025 | $8.6B | +46% |
ASML's revenue has grown year over year for four quarters in a row: $13B last quarter, up 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | +12 points |
| Q2 2026 | 37% | +4.2 points |
| Q1 2026 | 36% | +1.4 points |
| Q4 2025 | 35% | -0.1 points |
| Q3 2025 | 33% | -3.4 points |
| Q3 2025 | 33% | +0.2 points |
| Q2 2025 | 35% | +5.3 points |
| Q1 2025 | 35% | +9.1 points |
ASML has the edge over COHR on profitability, with a higher operating margin.
COHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +50% |
| Q2 2026 | $2B | +34% |
| Q1 2026 | $1.8B | +21% |
| Q4 2025 | $1.7B | +17% |
| Q3 2025 | $1.6B | +17% |
| Q2 2025 | $1.5B | +16% |
| Q1 2025 | $1.5B | +24% |
| Q4 2024 | $1.4B | +27% |
COHR has the edge over ASML on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.4 points |
| Q2 2026 | 14% | +18 points |
| Q1 2026 | 10% | +9.6 points |
| Q4 2025 | 10% | +1 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | -4.2% | -9 points |
| Q1 2025 | 0.7% | -1.2 points |
| Q4 2024 | 8.9% | +6.1 points |
COHR's operating margin was 15% last quarter, up 1.4 points from the same quarter a year ago, near the top of its range since 2019.
ASML Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.6B | +4571% |
| Q2 2026 | $1.6B | +292% |
| Q1 2026 | -$2.9B | -$2.4B |
| Q4 2025 | $12.2B | +24% |
| Q3 2025 | $270.7M | -54% |
| Q3 2025 | $270.7M | -54% |
| Q2 2025 | $397.4M | -10% |
| Q1 2025 | -$527.8M | +$223M |
ASML has the edge over COHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
COHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$868.2M | -$810.2M |
| Q2 2026 | -$486.2M | -$485.2M |
| Q1 2026 | -$383.5M | -850% |
| Q4 2025 | -$95.7M | -217% |
| Q3 2025 | -$58M | -195% |
| Q2 2025 | -$1.1M | -102% |
| Q1 2025 | $51.1M | +111% |
| Q4 2024 | $81.7M | +$106M |
COHR's free cash flow has turned negative after years in the green: −$1.8B over the past year.
ASML Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.4M shares |
| 1 year | -1.1% | -4.1M shares |
| 3 years | -2.6% | -10.3M shares |
| 5 years | -5.3% | -21.5M shares |
| Available history | -8.6% | -36.2M shares |
ASML has the edge over COHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.5B |
| Q2 2026 | $1.2B |
| Q1 2026 | $1.1B |
| Q4 2025 | $1.9B |
| Q3 2025 | $191.3M |
| Q3 2025 | $191.3M |
| Q2 2025 | $1.6B |
| Q1 2025 | $2.9B |
ASML spent $8.7B buying back its own shares over the past year.
COHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.4% | +6.6M shares |
| 1 year | +5.9% | +11.3M shares |
| 3 years | +34% | +51.7M shares |
| 5 years | +74% | +86.2M shares |
| Available history | +122% | +111M shares |
COHR has 202M diluted shares, up 5.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q2 2020 | — |
| Q1 2020 | $1,000 |
ASML Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -0.0x | Net Cash |
| Q2 2024 | -0.0x | Net Cash |
ASML has the edge over COHR on leverage, with a lower net debt burden relative to earnings.
COHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 4.6x | High |
COHR's net debt is about 1.7 years of its operating earnings (EBITDA), down from 4.1 years a year ago.
ASML Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 16.3 | Oversold |
ASML's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
COHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 16.5 | Oversold |
COHR's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
ASML PE vs Technology Sector
| Metric | ASML | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 28x | 38% above |
| PE % | 30 | 35 | 5 pts below |
ASML has the edge over COHR on valuation relative to its sector.
COHR PE vs Technology Sector
| Metric | COHR | Sector median | Relative |
|---|---|---|---|
| PE | 48x | 28x | 72% above |
| PE % | 58 | 35 | 23 pts above |
COHR is trading at 48x earnings, a 72% premium to the Technology sector's median of 28x.
ASML Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,636.6 | 8.5% below |
| 20 week MA | $1,696.6 | 12% below |
| 50 week MA | $1,531.1 | 2.2% below |
| 100 week MA | $1,160.1 | 29% above |
| 200 week MA | $964.4 | 55% above |
ASML has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 55% above its 200-week average.
COHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $252.9 | 8.2% below |
| 20 week MA | $284.1 | 18% below |
| 50 week MA | $277.7 | 16% below |
| 100 week MA | $185.9 | 25% above |
| 200 week MA | $120.6 | 92% above |
COHR has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 92% above its 200-week average.
ASML Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.7 | $483.1 | +63% |
| 2021 | $483.1 | $801.4 | +66% |
| 2022 | $801.4 | $551.4 | -31% |
| 2023 | $551.4 | $756.9 | +37% |
| 2024 | $756.9 | $713.6 | -5.7% |
| 2025 | $713.6 | $1,072.8 | +50% |
| 2026 YTD | $1,072.8 | $1,497.1 | +40% |
ASML has the edge over COHR on returns for 2026, with the stronger performance.
COHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.5 | $77.8 | +132% |
| 2021 | $77.8 | $68.0 | -13% |
| 2022 | $68.0 | $33.1 | -51% |
| 2023 | $33.1 | $43.5 | +32% |
| 2024 | $43.5 | $97.0 | +123% |
| 2025 | $97.0 | $191.7 | +98% |
| 2026 YTD | $191.7 | $232.1 | +21% |
COHR's yearly returns have swung widely, from +132% in 2020 to −51% in 2022. It's up 21% so far in 2026.